Healthrageous, Inc., a digital health management company, has launched the SMART Study to evaluate a digital technology enabled self-management solution to potentially improve the health status of people with type 2 diabetes. The study was launched together with Germany based, Boehringer Ingelheim and United BioSource Corporation (UBC).

The goal of the solution is to leverage technology in a way that makes the personalized journey of self-managing diabetes easier for patients to self-manage their disease.

Through this Institutional Review Board (IRB) approved research project, adults who have been diagnosed with type 2 diabetes for at least six months will have access to Healthrageous’ digital diabetes self-management programme. The web and smartphone delivered program will include a personalized action plan with health behavior improvement goals, a wireless glucose meter transmitting data to clinical monitors, as well as HbA1c at-home test kits. By combining medical claims data, this collaboration will allow an evaluation of the impact a digital diabetes platform could have on medical and pharmaceutical costs, clinical care, consumer behavior modification and device and self-reported biometric health measures.

UBC will identify and help manage the recruitment of participants from nearly a dozen large US employers for the study.

"Through a truly innovative, patient-centric design, this study will allow us to collect and integrate patient-reported data, biometric data and claims data in order to generate new insights into health behaviors, outcomes and cost utilization," said Abbe Steel, vice president, Patient & Physician Services, UBC.

"Innovations in machine learning and technology offer the opportunity to create and deliver a unique experience for each person with type 2 diabetes," said Rick Lee, president and CEO, Healthrageous. "We are delighted to be working with Boehringer Ingelheim and UBC on this first-of-its-kind evaluation of the promise that digital technology holds in stemming the type 2 diabetes epidemic."

"Boehringer Ingelheim is committed to innovation in diabetes treatment and strives for solutions that offer a "beyond pill” approach in health care,” said Klaus Wilgenbus, SVP, PM, Business Development, Licensing & Strategy at Boehringer Ingelheim. "As part of our ongoing collaboration with Healthrageous, this project adds nicely to our goal to provide and develop solutions for patients and their families that contribute to a more holistic way of diabetes treatment."

Healthrageous, Inc. is an accountable health company that supports individual journeys to prevent and self-manage chronic health conditions via the web and a mobile app.

United BioSource Corporation (UBC), a subsidiary of Express Scripts Holding Company, leads the market in providing integrated, comprehensive clinical, safety, and commercialization services.